Context Therapeutics (CNTX) Competitors

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 3.0% of Context Therapeutics shares are held by insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Theravance Biopharma has a net margin of 98.54% compared to Context Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 16.76% beat Context Therapeutics' return on equity.

Context Therapeutics currently has a consensus price target of $6.60, suggesting a potential upside of 170.49%. Theravance Biopharma has a consensus price target of $21.83, suggesting a potential upside of 30.50%. Given Context Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Context Therapeutics is more favorable than Theravance Biopharma.

Theravance Biopharma has higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

In the previous week, Context Therapeutics and Context Therapeutics both had 2 articles in the media. Context Therapeutics' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.09 indicating that Context Therapeutics is being referred to more favorably in the media.

Context Therapeutics has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500.

Arbutus Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 13.77%. Context Therapeutics has a consensus price target of $6.60, suggesting a potential upside of 170.49%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Arbutus Biopharma.

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 20.3% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 3.0% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Context Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 2 mentions for Context Therapeutics and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.27 beat Context Therapeutics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Context Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -237.88%. Arbutus Biopharma's return on equity of -42.39% beat Context Therapeutics' return on equity.

Arbutus Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Arbutus Biopharma has higher revenue and earnings than Context Therapeutics. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Design Therapeutics' return on equity of -33.07% beat Context Therapeutics' return on equity.

Design Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Design Therapeutics had 9 more articles in the media than Context Therapeutics. MarketBeat recorded 11 mentions for Design Therapeutics and 2 mentions for Context Therapeutics. Design Therapeutics' average media sentiment score of 0.62 beat Context Therapeutics' score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the media.

Design Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 23.04%. Context Therapeutics has a consensus price target of $6.60, suggesting a potential upside of 170.49%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Design Therapeutics.

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 23.5% of Design Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Design Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

In the previous week, Kura Oncology had 3 more articles in the media than Context Therapeutics. MarketBeat recorded 5 mentions for Kura Oncology and 2 mentions for Context Therapeutics. Kura Oncology's average media sentiment score of 0.41 beat Context Therapeutics' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media.

Kura Oncology presently has a consensus price target of $26.38, suggesting a potential upside of 183.91%. Context Therapeutics has a consensus price target of $6.60, suggesting a potential upside of 170.49%. Given Kura Oncology's higher possible upside, equities research analysts plainly believe Kura Oncology is more favorable than Context Therapeutics.

Context Therapeutics has lower revenue, but higher earnings than Kura Oncology. Context Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

14.0% of Context Therapeutics shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 3.0% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Context Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -412.95%. Context Therapeutics' return on equity of -47.04% beat Kura Oncology's return on equity.

Kura Oncology has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.